Leflunomide: A novel drug for pharmacological immunomodulation;Leflunomid - Ein neues medikament zur pharmakologischen immunmodulation

Hautarzt

Volumn 53, Issue 5, 2002, Pages 309-315

  Wozel, G ^a   Pfeiffer, C ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Clinical application; Dermatological use; Immunomodulation; Leflunomide; Mechanism of action

Indexed keywords

ANALGESIC AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; ASCOMYCIN; AZATHIOPRINE; CARMUSTINE; CYCLOSPORIN A; CYTOSTATIC AGENT; DRUG METABOLITE; GLUCOCORTICOID; GOLD DERIVATIVE; IMMUNOMODULATING AGENT; INDOMETACIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLAMINE; PIMECROLIMUS; PLACEBO; PREDNISOLONE; RAPAMYCIN; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; TERIFLUNOMIDE;

ANIMAL MODEL; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG STRUCTURE; GLIOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; MULTICENTER STUDY; NONHUMAN; OVARY TUMOR; PEMPHIGOID; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CARCINOMA; PSORIASIS; PSORIASIS VULGARIS; RAT; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; UVEITIS;

EID: 0036944304     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050100287     Document Type: Review

References (40)

1. AHFS DRUG Information (2000) Current Developments. Leflunomide [Suppl A]. In: McEvoy GK (ed) American Society of Health-System Pharmacists. Bethesda, USA pp 8-15
2. Bartlett RR (1995) An introduction to leflunomide. In: Bartlett RR (ed) Leflunomide. Proceedings of the Vienna Symposium, 12 October 1993. Birkhäuser, Basel Boston Berlin, pp 9-14
3. Blümlein K, Pfeiffer C, Wozel G (2000) Eotaxin levels in peripheral blood are increased in patients with bullous pemphigoid (abstract). XXVII. Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung Vienna. Arch Dermatol Res 292:145
4. Cao WW, Kao PN, Aoki Y (1996) A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immuno-suppressive cytokine, TGF-β 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 28:3079-3080
5. Dimitrijevic M, Bartlett RR (1996) Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatic arthritis. Inflamm Res 45:550-556
6. Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Chong AS (1997) The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 159:22-27
7. Fox RI (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol [Suppl 53]:25:20-26
8. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Kirschbaum BJ (1999) How does leflunomide modulate the immune response in rheumatoid arthritis? BioDrugs 12:301-315
9. Glant TT, Mikecz K, Brennan F, Negroiu G, Bartlett R (1994) Suppression of autoimmune responses and inflammatory events by leflunomide in an animal model for rheumatoid arthritis. Agents Actions 41:267-270
10. Graul A, Castaner J (1998) Leflunomide. Drugs Fut 23:827-837
11. Hamilton LC, Vojnovic I, Bakhle Y (1996) The anti-inflammatory drug leflunomide inhibits in vitro and in vivo the activity of COX-2 or iNOS (abstract). Proc Br Pharmacol Soc 18:51
12. Hamilton LC, Vojnovic I, Wamer TD (1999) A77 1726, the active metabolite of leflunomide, directly inhibits the activity of cyclooxygenase-2 in vitro and in vivo in a substrate-specific manner. Br J Pharmacol 127:1589-1596
13. Johnston GA, Rees JL, Reynolds NJ (1997) Leflunomide therapy in severe, unstable psoriasis. Australas J Dermatol [Suppl 2] 38:2062
14. Kalden JR (1999) Changing the course of rheumatoid arthritis. Scand J Rheumatol [Suppl 112] 28:1-35
15. th Congress of the European Academy of Allergology and Clinical Immunology, Berlin, 9-13 May, Allergy Band 56: Suppl. 68
16. Klingemann HG (1995) Update on immunosuppressive drugs. A report from the International Consensus Conference on Immunosuppressive Drugs, May 4-6, Lake Louise, Canada, DN & P 8,303-309
17. Knecht W, Löffler M (1998) Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchonic acid derivatives. Biochem Pharmacol 56:1259-1264
18. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP (2000) Inhibition of neutrophil migration soon after initiation of treatment wih leflunomide or methotrexate in rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 43:1488-1495
19. Kremer JM, Caldwell JR, Cannon GW, Genovese M, Cush JJ, Bathon J, Coleman JC (2000) The combination of leflunomide (LEF) and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who are failing on MTX treatment alone: a double-blind placebo (PLC) controlled study. Arthritis Rheum [Suppl 9] 43:224
20. Kurtz ES, Bailey SC, Arshad F, Lee AA, Przekop PA (1995) Leflunomide: An active anti-inflammatory and antiproliferative agent in models of dermatologic disease. Inflamm Res [Suppl 2] 44:187-188
21. Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J (2000) Structures of human dihydroorotate dehydrogenase in complex wiith antiproliferative agents. Structure Fold Des 8:25-33
22. Manna SK Mukhopadhyay A, Aggarwal BB (2000) Leflunomide inhibits TNF-induced cellular responses: effects on NFKB, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 165:5962-5969
23. Mladenovic V, Domljan Z, Rozman B et al. (1995) Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 38:1595-1603
24. Nair RV, Cao W, Morris RE (1996) The antiproliferative effect of leflunomide on vascular smooth muscle cells in vitro is mediated by selective inhibition of pyrimidine synthesis. Transplant Proc 28:3081
25. Nousari, HC, Anhalt GJ (2000) Bullous pemphigoid treated with leflunomide. A novel immunomodulatory agent. Arch Dermatol 136:1204-1205
26. Parnham MJ (1995) Leflunomide: a potential new disease-modifying anti-rheumatic drug. Exp Opin Invest Drugs 4:777-779
27. Popovic S, Bartlett R (1986) Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents Actions 19:313-314
28. Poppe C, Wozel G, Pfeiffer C (2001) Eotaxin and IL-5 are associated with an intense infiltrate of activated eosinophils in Herpes gestationis (HG) (abstract). XXVIII Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung, München 15-17. Februar. Arch Dermatol Res 293:71
29. Robertson SM, Lang LS (1994) Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions 42:167-172
30. Rückemann K, Fairbanks L, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, Simmonds HA (1998) Leflunomide inhibits pyrimidine de novo synthesis in mitogenstimulated lymphocytes from healthy humans. J Biol Chem 273:21682-21691
31. Silva jr HT, Morris RE (1997) Leflunomide and malononitriloamides. Exp Opin Invest Drugs 6:51-64
32. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan (1996) Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61:635-42
33. Smolen JS, Kalden JR, Scott DL et al. (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353:259-266
34. Strand V, Cohen S, Schiff M, Weaver A et al. (1999) Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Intern Med 159:2542-2550
35. Swan SK, Crary GS, Guijarro C, O'Donnell, MP, Keane WF, Kasiske BL (1995) Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. Transplantation 60:887-890
36. Thoss K, Henzgen S, Petrow PK, Katenkamp D, Bräuer R (1996) Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclospotin A. Inflamm Res 45:103-107
37. Weinblatt ME, Kremer JM, Coblyn JS et al. (1997) Leflunomide plus methotrexate in refractory rheumatoid arthritis: a pilot study (abstract). Arthritis Rheum [Suppl 9] 40:193
38. Weinblatt ME, Kremer JM, Coblyn JS et al. (1999) Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 42:1322-1328
39. Wozel G, Mrowietz U (1999) The psoriasis plaque test on the stage. Acta Dermatovenerol A.P.A. 8:43-49
40. Xu X, Williams JW, Gong H, Finnegan A, Chong AS (1996) Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 52:527-534